Role of platelet-activating factor in functional alterations induced by xenoreactive antibodies in porcine endothelial cells

Transplantation

Volumn 70, Issue 8, 2000, Pages 1198-1205

  Biancone, Luigi ^a   Cantaluppi, Vincenzo ^a   Segoloni, Giuseppe ^a   Boccellino, Mariarosaria ^a   Del Sorbo, Lorenzo ^a   Conaldi, Pier Giulio ^b   Tjoelker, Larry W ^c   Maruyama, Shoici ^d   Cantu, Edward ^d   Stern, David ^d   Andres, Giuseppe ^d   Camussi, Giovanni ^a,e  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c ELI LILLY AND COMPANY   (United States)

^d College of Physicians and Surgeons ^*  (United States)

^e MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GALACTOSE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ANIMAL CELL; ARTICLE; BABOON; CELL ADHESION; CELL MOTILITY; CELL SHAPE; CELL STIMULATION; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MONOLAYER CULTURE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SWINE; XENOGRAFT;

EID: 0034721911     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200010270-00013     Document Type: Article

References (43)

1. Antibodies in graft rejection
2. The α Galactosyl epitope (Galα1-3Galβ1-4GlcNac-R) and natural anti-Gal antibody
3. Delayed xenograft rejection
4. Acute vascular rejection
5. Humoral responses in pig-to-baboon cardiac transplantation: Implication for the pathogenesis and treatment of acute vascular rejection and for accomodation
6. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants
7. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: Type I activation
8. Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: Type II activation
9. Hyperacute renal allograft rejection in the rabbit. The role of platelet-activating factor and of cationic proteins derived from polymorphonuclear leukocytes and from platelets
10. Platelet-activating factor and hyperacute rejection. The effect of a platelet-activating factor antagonist, SR163-441, on rejection of xenografts and allografts in sensitized hosts
11. Effect of a platelet-activating factor (PAF) receptor antagonist on hyperacute xenograft rejection; evaluation in a pig kidney-human blood xenoperfusion model
12. Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys
13. Platelet-activating factor produced by endothelial cells: A molecule with autocrine and paracrine properties
14. Immunochemical quantitation of antigens by single radial immunodiffusion
15. Man, apes and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells
16. Determination of aminosugar linkage in glycolipids by methylation. Aminosugar linkage of ceramide pentasaccharides of rabbit erythrocytes and Forssman antigen
17. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G
18. The porcine endothelial cell in tissue culture
19. Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus
20. Plasma platelet-activating factor acetylhydrolase is a secreted phospholipase A2 with a catalytic triad
21. Outer-membrane porins from Gram-negative bacteria stimulate platelet-activating factor biosynthesis by cultured human endothelial cells
22. Structural analysis of purified platelet activating factor by lipases
23. Direct visualization and quantification of cellular cytotoxicity using two colour fluorescence
24. Tumor necrosis factor alters cytoskeletal organization and barrier function of endothelial cells
25. Histamine type I receptor occupancy increases endothelial cytosolic calcium, reduces F-actin and promotes albumin diffusion across cultured endothelial monolayer
26. Interaction of baboon anti-α-Galactosyl antibody with pig cells and tissues
27. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet-activating factor
28. CV 3988: A specific antagonist of platelet-activating factor (Paf-acether)
29. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo
30. Platelet-activating factor primes neutrophil responses to agonists: Role in promoting neutrophil-mediated endothelial damage
31. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury
32. Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice
33. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy
34. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts
35. Neutrophil adhesion to human endothelial cells is induced by the membrane attack complex: The role of P-selectin and platelet activating factor
36. Significance of anti-Gal IgG in chronic xenograft rejection
37. Porcine and bovine cartilage transplants in cynomolgus monkey. II. Changes in anti-Gal response during chronic rejection
38. Increased anti-Gal activity in diabetic patients transplanted with fetal porcine islet cell clusters
39. The humoral immune response in humans following cross-perfusion of porcine organs
40. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase
41. Effect of recombinant platelet-activating factor acetylhydrolase on two models of experimental acute pancreatitis
42. T cell independence of macrophage and natural killer cell infiltration, cytokine production, and endothelial activation during delayed xenograft rejection
43. Transient perturbation of endothelial integrity induced by natural antibodies and complement